Survival Analysis Techniques in Clinical Trials

Survival analysis in clinical trials addresses the timing of events such as death, disease progression or relapse. Key challenges include handling right-censored data—where a patient’s event time is unknown beyond a follow-up point—and accommodating varying hazard patterns over time. Non-parametric methods, notably the Kaplan–Meier estimator and the log-rank test, remain standard for estimating survival curves and comparing groups under the proportional hazards assumption. Semi-parametric approaches, chiefly the Cox proportional hazards model, permit covariate adjustment without specifying the baseline hazard. Parametric models, using distributions such as exponential or Weibull, can increase precision when their assumptions hold and enable extrapolation beyond the observation period. Recent advances extend classical tools to settings with non-proportional hazards by employing weighted log-rank tests, combined hypothesis tests and alternative estimands such as the restricted mean survival time. These techniques support flexible trial design, facilitate interpretation when hazards cross or vary, and improve precision in small or early-phase studies. The global impact of these methods is reflected in personalised treatment strategies, more efficient sample size computations and enhanced regulatory decision making across oncology, cardiology and infectious disease trials.

Research from Nature Portfolio

One recent study demonstrated that survival data from numerous phase III oncology trials can be well modelled by two-parameter Weibull distributions. By reconstructing individual participant data from published Kaplan–Meier curves, researchers showed that parametric fitting markedly increases the precision of survival estimates in small cohorts, making a 50-patient arm as precise as a conventional 90-patient analysis. The work also revealed frequent deviations from proportional hazards, particularly in trials of immune checkpoint inhibitors, and highlighted how trial duration influences the likelihood of demonstrating treatment benefit when hazards vary over time.

Survival Analysis Techniques in Clinical Trials publication trend

The graph below shows the total number of articles in survival analysis techniques in clinical trials across all publications each year (not limited to Nature Index journals).

Technical terms

Time-to-event outcome: The duration from a defined origin (e.g. randomisation) to the occurrence of a specified event.

Censoring: Instances where the event has not occurred by the end of observation or loss to follow-up occurs.

Hazard function: The instantaneous event rate at time t given survival until t.

Proportional hazards assumption: The requirement that hazard ratios between groups remain constant over time.

Kaplan–Meier estimator: A non-parametric estimator of the survival function that accounts for censored observations.

Log-rank test: A non-parametric test comparing survival curves under the proportional hazards assumption.

Cox proportional hazards model: A semi-parametric regression model estimating hazard ratios while leaving the baseline hazard unspecified.

Restricted mean survival time: The expected survival time up to a pre-specified time point, equivalent to the area under the survival curve.

Weighted log-rank test: A variant of the log-rank test that applies time-dependent weights to emphasise early or late differences in hazards.

References

1. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Medical Research Methodology (2013).
2. Statistical Inference Methods for Two Crossing Survival Curves: A Comparison of Methods. PLOS ONE (2015).
3. Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology. Pharmaceutical Statistics (2020).
4. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nature Communications (2022).